Recorded device evidence

Q2 Blood Administration Sets (K213846): indications, design and recorded evidence

The acquired K213846 file contains product-specific indications and users, design and operating principle, recorded comparison and differences, non-clinical evidence actually described, performance evidence actually described, clinical evidence or its stated absence sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 59 selected decisions under primary code FPA. 59 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 137.5, median 223.0, upper quartile 279.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K213846 ↗ · this pageQ2 Blood Administration Sets2021-12-10 → 2022-06-05177Traditional
K254123 ↗Ecomed Disposable Administration Sets2025-12-19 → 2026-09-11266Abbreviated
K261530 ↗iiSure Infusion Set2026-05-08 → 2026-06-0326Special
K252543 ↗AMSafe Administration Set (BA-70075, BA-70071-D, BA-70070, BA-70071-P, BA-70072, BA-70072-F, BA-70071-DF, BA-70071-DF-120, FE01, FE04)2025-08-12 → 2026-05-04265Traditional
K251375 ↗PuraCath Firefly Needleless Connector IT (9005)2025-05-02 → 2026-02-12286Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K213846 · PDF page 3 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K213846 · PDF page 5 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Recorded comparison and differences

K213846 · PDF page 6 ↗ Source 4

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

Non-clinical evidence actually described

K213846 · PDF page 8 ↗ Source 5

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Performance evidence actually described

K213846 · PDF page 8 ↗ Source 5

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Clinical evidence or its stated absence

K213846 · PDF page 9 ↗ Source 6

Not applicable. Clinical testing was not performed to support these 510(k) submissions.

Compare with your product: Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Historical references beside dated FDA recognition metadata

Read each mention in the linked original summary, including statements that testing was not performed. Recognition metadata does not determine your testing needs, chosen edition or transition eligibility.

Reference in this historical summaryDesignation in the acquired FDA exportRecognition / entry dateRecorded transition-expiration dateSources
ISO 1135-4:2015
Nonclinical Testing Summary
ISO 1135-4 Seventh edition 2025-05
Transfusion equipment for medical use-Part 4: Transfusion sets for single use gravity feed
6-514 · Complete
12/22/2025
Not recorded in this export rowSummary [5] · Metadata [7]
Read scope and recognition limits ↗
ISO 1135-4:2015
Nonclinical Testing Summary
ISO 1135-4 Sixth edition 2015-12-01
Transfusion equipment for medical use-Part 4: Transfusion sets for single use gravity feed
6-384 · Complete
08/21/2017
12/17/2028Summary [5] · Metadata [8]
Read scope and recognition limits ↗
ISO 80369-7:2016
Nonclinical Testing Summary
ISO 80369-7 Second edition 2021-05
Small-bore connectors for liquids and gases in healthcare applications - Part 7: Connectors for intravascular or hypodermic applications
5-133 · Complete
12/21/2020
Not recorded in this export rowSummary [5] · Metadata [9]
Read scope and recognition limits ↗

Prepare for your provider: the proposed protocol/report edition, its justification for your device and the complete current FDA recognition sheet. In particular, inspect exclusions for partial recognition. An edition difference does not automatically make the historical evidence unusable.

Identifier-matching method and selection limits

Match explicit ISO/IEC identifiers in selected preserved summary excerpts to the acquired, count-reconciled FDA metadata export. Preserve the historical edition mention, current snapshot designations, entry dates, recognition extent and any recorded transition-expiration date as separate facts. No title-similarity, edition-equivalence, test-mandate or transition-eligibility inference. At most twenty matched occurrences and thirty metadata rows per reference; wide matches are held for separate review.

2 of 2 matched reference occurrences shown.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK213846 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryQ2 Blood Administration Sets [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantQuest Medical, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeFPA [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2022-06-05 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2021-12-10 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Recorded comparison and differences — what differs in our product?

    The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

    Useful evidence: Feature-by-feature differences and the underlying cited documents; no automated predicate selection.

  4. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

  5. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

  6. Clinical evidence or its stated absence — what differs in our product?

    Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

    Useful evidence: Your proposed claims and supporting evidence, plus a reviewed rationale for clinical-evidence needs.

  7. Which edition and recognition limits would our provider rely on?

    Compare each historical reference below with the dated FDA metadata. Ask the specialist to justify the applicable scope and selected edition, read the complete supplementary sheet for partial-recognition exclusions, and investigate any recorded transition conditions. A difference in editions does not automatically make the earlier study unusable.

    Useful evidence: Proposed protocol/report edition, dated FDA recognition sheet with scope/exclusions, and a documented edition/transition rationale for the actual device.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[87073] · record 76d1f547fe923ce372371d81b8aa62f1f94be3c00a82b29414a531868a5b9329
  • [10] Complete results array / fda-decision-context:K213846 · record whole dataset partition

FDA 510(k) summary — K213846 ↗

Tue, 07 Jun 2022 04:00:10 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot a894c3a4fe7b79fe874f1ac06366b7a331417081d7d665b707cb22a9876e4af8

  • [2] PDF page 3 · record 13f08862431344793aea6fb514715e45eedee1e3a5933f14ff57f61b0c80b105
  • [3] PDF page 5 · record 9769ec4c587d7150e5cc9d10a29cdbab5624c62e141f71c84da98c497c9c2a35
  • [4] PDF page 6 · record 580a97d993482c59db8536644be84d009a3814b347136b2988173e29acc159d2
  • [5] PDF page 8 · record 241c83e48f04dca74f8ee646b8ba58b9d736e8fc18fb9c651af59f12bfef1713
  • [6] PDF page 9 · record b0e79262e5c4861356df8941839565a67ccce2665d0a637c2c5405329f4ba9ac

FDA — recognition metadata exported through the official search form ↗

Version not stated by the source · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 94ccf56dc846c7f6d78d6ad77dc6e87d1803ac3612af01d6894949e34c4a78d8

  • [7] CSV row 121 · record 9e2b78492e4ab4eb6fefd147ef774372134b1c172bb3867366182f3939a354ae
  • [8] CSV row 1386 · record f58972cc5aafb57f5ca07e41b2acdac5f9c88903b22d6f522ece460846da5634
  • [9] CSV row 875 · record d217d776a2a05479cf863da59b976a172ab4080187ba1c107c17e22da12d893f

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services